Cochrane COVID-19 Study Register
Study record
IRCT20180425039414N2 // U07First Published: 2020 Jun 9Updated Date: 2021 Jan 29

The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (7)
  2. Male and Female
  3. COVID-19
  4. Adult
  5. Aged (65+)
  1. Intervention (1)
  2. Zinc
  1. Comparison (1)
  2. Hydroxychloroquine Sulfate
  1. Outcome (5)
  2. Fever
  3. Hospitalism
  4. Death
  5. Dyspnea
  6. Cough
Reference record

The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19)

IRCT20180425039414N2, U07
Trial registry record
No Results
Study aim The effect of zinc on the treatment and clinical course of patients with SARS-cov2 (COVID-19) Inclusion criteria: 18 years of age or olderDiagnosis of COVID-19 by RT PCR and CT scan of the lungsBlood oxygen levels are between 90 and 93 percentBreathing rate between 20 and 24 per minuteHeart rate between 100 and 130 beats per minute Primary outcome: Clinical response. Timepoint: During hospitalization. Method of measurement: Cessation of fever, improvement of shortness of breath, reduction of cough, blood oxygenation (SaO2) and hemodynamic parameters.; Mortality. Timepoint: During hospitalization. Method of measurement: Count the number of dead patients.; Hospital stay. Timepoint: During hospitalization. Method of measurement: Count the number of hospital days to improve clinical symptoms. Intervention: Intervention 1: Intervention group: Includes 40 patients with COVID-19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours. In addition to the above, zinc tablets with a dose of 220 mg twice a day orally during the patient's hospitalization will be prescribed. Intervention 2: Control group: Includes 40 patients with COVID-19 which for 5 days, who are given two 200 mg hydroxychloroquine sulfate tablets every 12 hours on the first day and then 200 mg every 12 hours